Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street to higher close as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| (NASDAQ: CNTB) | Delayed: 0.80 -0.08 (9.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.88 | 52 Week High | $ | |||
| Open | $0.88 | 52 Week Low | $ | |||
| Day High | $0.90 | P/E | N/A | |||
| Day Low | $0.79 | EPS | $ | |||
| Volume | 1,567,844 | |||||
